1.Differentially expressed proteins in interosseous muscle tissue between patients with familial amyotrophic lateral sclerosis and normal individuals in a family
Journal of Apoplexy and Nervous Diseases 2025;42(1):3-8
Objective To investigate the differential expression of related proteins in interosseous muscle tissue between patients with familial amyotrophic lateral sclerosis(FALS) and normal individuals in a family using the isobaric tags for relative and absolute quantitation (iTRAQ) technique, to identify the pathogenic proteins for this family, and to provide a basis for treatment. Methods Interosseous muscle tissue samples were collected from all subjects in this family, and the iTRAQ technique was used to perform qualitative and quantitative analyses for all proteins and obtain the expression profile of proteins in the disease group and the normal group. The bioinformatics methods were used to identify the proteins associated with the onset of FALS. A gene ontology(GO)analysis was performed for cell components, and a classification analysis was performed for related proteins. Results A total of 453 proteins were identified by mass spectrometry. The GO analysis obtained 14 differentially expressed proteins between the disease group and the normal group (P<0.05), and compared with the normal group,the disease group had the low expression of 5 proteins (Ratio<1) and the high expression of 9 proteins (Ratio>1). Conclusion This study identifies 8 proteins that are highly associated with FALS, i.e., tripartite motif-containing protein 72, NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1, annexin A1, decorin, glutathione peroxidase 3, collagen alpha-1 (Ⅻ) chain, collagen alpha-2 (Ⅰ) chain, and collagen type I alpha 1 isoform CRA-a. There are 6 proteins that might be associated with FALS, i.e.,26 S protease regulatory subunit 8, laminin subunit alpha-2,prolargin, fibrillin-1, myosin-8, and dermatopontin.
Proteomics
2.Serological characteristics and bioinformatics analysis of 4 blood donors with RHCE*cE(281C,282T) variant allele.
Fan WU ; Naibao ZHUANG ; Liyan SUN ; Tong LIU ; Yanlian LIANG ; Shuang LIANG
Chinese Journal of Medical Genetics 2025;42(2):137-144
OBJECTIVE:
To explore the serological characteristics and bioinformatics analysis results of 4 blood donors with RHCE*cE(281C, 282T) variant allele.
METHODS:
A total of 4 non-related blood donors with RHCE*cE (281C, 282T) variant allele (donors 1-4) were selected as the study objects. They donated blood at Shenzhen Blood Center from January 2022 to June 2023. The 4 blood donors were all Han. And 5 mL elbow venous blood was collected from these 4 blood donors. Regular serological assaying with 4 kinds of monoclonal antibody reagents was used for determination of the RhCcEe type. The nucleotide sequences of all 10 exons and adjacent flanking intron regions of RHCE gene in these 4 donors were analyzed by Sanger sequencing, and the full-length haplotype analysis of RHCE gene was performed by using the single-molecule real-time sequencing (SMRT) third-generation technology. DeepTMHMM software was used to analyze the structure of protein transmembrane region of wild type and variant RhCcEe protein and predict the location of amino acid substitution. The effects of mutations on RhCcEe protein function were analyzed using PolyPhen-2, SIFT and Mutation Taster bioinformatics software. Robetta and Swiss-PdbViewer v4.1.0 were used for modeling the tertiary structures of RhCcEe to analyze the difference between wild type and variant RhCcEe protein. The mutation was rated according to the standards and guidelines for the classification of genetic variants of the American College of Medical Genetics and Genomics (ACMG). This study has been approved by the Medical Ethics Committee of Shenzhen Blood Center (Approval No. SZBCMEC-2022-024).
RESULTS:
The RhCcEe phenotypes of the 4 blood donors were CCEweake by serological assaying. The RhE antigen were weakly expressed form 0 to 3+. The analysis of RHCE gene sequence indicated that all the 4 donors with RHCE*cE (281C, 282T) allele. The mutation caused the substitution of a single amino acid in the RhCcEe protein (p.Leu94 Pro) and the amino acid substitution was located in the transmembrane α3 chain resulted in significant changes in the 3D structure of the extracellular region of RhCcEe protein. The substitution was predicted to be "Probably damaging", "Damaging" and "Polymorphism" by PolyPhen-2, SIFT and Mutation Taster bioinformatics software. According to the guidelines of ACMG, the variant was rated to be likely pathogenic.
CONCLUSION
The RHCE*cE (281C, 282T) variant allele was first found in the Han Chinese population. The serological data of this allele were enriched. It provides an important guarantee for the safety of blood transfusion. Bioinformatics analysis provided evidences for further study of the structure and functions of RhCcEe protein.
Humans
;
Blood Donors
;
Computational Biology/methods*
;
Alleles
;
Rh-Hr Blood-Group System/genetics*
;
Male
;
Female
;
Adult
;
Exons
3.Key updates in the 2024 Edition of the International System for Human Cytogenomic Nomenclature (ISCN).
Hao WANG ; Yi LAI ; Juan WEN ; Na HAO
Chinese Journal of Medical Genetics 2025;42(7):848-854
The International System for Human Cytogenomic Nomenclature (ISCN) is a standardized international nomenclature system established by the International Standing Committee on Human Cytogenomic Nomenclature (ISCN SC). It is designed for describing chromosomal or genomic abnormalities detected by commonly used genetic and genomic techniques including but not limited to karyotyping, fluorescence in situ hybridization, microarray, genome mapping, various region-specific assays, and high-throughput sequencing. With a history spanning over six decades, the ISCN was revised by the ISCN SC in 2024 and officially published in September 2024. This article provides a summary for the updates introduced in the 2024 edition of the International System for Human Cytogenomic Nomenclature.
Humans
;
Terminology as Topic
;
Genomics
;
Genome, Human/genetics*
4.Applications and Advances of Metabolomics in Lung Cancer Research.
Daoyun WANG ; Zhicheng HUANG ; Bowen LI ; Yadong WANG ; Zhina WANG ; Nan ZHANG ; Zewen WEI ; Naixin LIANG ; Shanqing LI
Chinese Journal of Lung Cancer 2025;28(7):533-541
Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading cause of cancer-related mortality worldwide. In recent years, metabolomics has emerged as a key systems biology approach for analyzing small-molecule metabolites in cells, tissues and organisms. It provides new strategies for early diagnosis and metabolic profiling. Additionally, metabolomics plays a crucial role in studying resistance mechanisms in lung cancer. Tumor cell metabolic reprogramming is a key driving factor in the initiation and progression of lung cancer. Metabolomics studies have revealed how lung cancer cells regulate critical pathways such as energy metabolism, lipid metabolism, and amino acid metabolism to adapt to the demands of rapid proliferation and invasive metastasis. This review summarizes the latest advances in metabolomics research in lung cancer, focusing on the characteristics of metabolic reprogramming, the identification of potential metabolic biomarkers, and the prospects of metabolomics in early diagnosis and the elucidation of resistance mechanisms in lung cancer.
.
Humans
;
Metabolomics/methods*
;
Lung Neoplasms/pathology*
;
Animals
;
Biomarkers, Tumor/metabolism*
5.Application of salivary micro-ecosystem in early prevention and control of oral and systemic diseases.
Xiangyu SUN ; Chao YUAN ; Xinzhu ZHOU ; Jing DIAO ; Shuguo ZHENG
Journal of Peking University(Health Sciences) 2025;57(5):859-863
Saliva is an important body fluid in the oral cavity containing lots of biomarkers, whose inherent micro-ecosystem holds significant value for early diagnosis and monitoring of oral diseases. Simultaneously, saliva has particular advantages, such as ease of sampling, painless and non-invasive collection, and suitability for repeated sampling, making it highly appropriate for surveillance and follow-up of diseases. In a series of studies conducted by the research group for preventive dentistry in Peking University School and Hospital of Stomatology, we compared different segments of saliva and those samples collected via different sampling methods using proteomic/peptidomic and microbiomic technologies to explore the stability of saliva samples. Besides, the significance of applying representative salivary biomarkers in early prevention and control of representative oral diseases (e.g. dental caries, periodontal diseases) and systemic conditions (e.g. type 2 diabetes mellitus, chronic kidney disease) was confirmed as well.
Humans
;
Saliva/chemistry*
;
Dental Caries/diagnosis*
;
Biomarkers/analysis*
;
Periodontal Diseases/diagnosis*
;
Mouth Diseases/diagnosis*
;
Proteomics/methods*
;
Diabetes Mellitus, Type 2/diagnosis*
;
Microbiota
;
Renal Insufficiency, Chronic/prevention & control*
6.Dihuang Yinzi Regulates cAMP/PKA/CREB-BDNF to Improve Synaptic Plasticity in APP/PS1 Mice: A Study Based on Brain Metabolomics.
Huan-Ning JIANG ; Bo ZHANG ; Jian ZHANG ; Yan-Yan ZHOU
Chinese journal of integrative medicine 2025;31(11):991-1000
OBJECTIVE:
To explore the mechanism of Dihuang Yinzi (DHYZ) in the treatment of Alzheimer's disease (AD) by integrating metabolomics and experimental verification.
METHODS:
Forty-eight male APP/PS1 mice were divided into model, high- (DHYZ-H), medium- (DHYZ-M), and low-dose DHYZ (DHYZ-L) groups (12 mice per group) according to a random number table. Mice in DHYZ groups were gavaged with DHYZ 6.34, 12.68, and 25.35 g/(kg·d), respectively. Twelve C57BL/6 mice were gavaged with distilled water as the blank group. Metabolomics was used to analyze differential metabolites in the brains of mice. Morris water maze test was used to detect the memory abilities of mice. The hematoxylin-eosin staining and transmission electron microscopy were used to observe the general morphology and ultrastructure of neurons. The enzyme-linked immunosorbent assay was used to detect the levels of superoxide dismutase (SOD), reactive oxygen species (ROS), and amyloid β -protein 1-42 (A β1-42). The real-time quantitative polymerase chain reaction was used to detect the mRNA expressions of density-regulated protein 1 (DRP1), fission 1 (FIS1), mitofusin-1 (MFN1), and optic atrophy protein 1 (OPA1). Western blot was used to detect the protein expressions of cyclic adenosine monophosphate (cAMP), protein kinase A (PKA), cAMP response binding protein (CREB), brain-derived neurotrophic factor (BDNF), synapsin 1 (SYN1), synaptophysin (SYP), and postsynaptic density protein 95 (PSD95).
RESULTS:
A total of 82 differential metabolites were identified in the brains of APP/PS1 mice, among which 7 differential metabolites could be regulated by DHYZ. After DHYZ intervention, the memory abilities of mice significantly increased (P<0.05 or P<0.01), the number of synapses and neurons in the hippocampus increased, and the mitochondrial morphology and structure were relatively intact. The DHYZ groups exhibited a significant reduction in hippocampal ROS and A β1-42 levels, along with a significant elevation in SOD level (P<0.05 or P<0.01). The mRNA expressions of DRP1 and FIS1 were reduced, while the mRNA expressions of MFN1 and OPA1 were increased after DHYZ treatment (P<0.05 or P<0.01). The cAMP/PKA/CREB-BDNF pathway was activated, and the expressions of SYN1, SYP and PSD95 proteins were significantly increased in the DHYZ-H group (P<0.05 or P<0.01).
CONCLUSIONS
DHYZ could improve mitochondrial dynamics and synaptic plasticity in APP/PS1 mice, inhibit oxidative stress, and thereby enhancing learning and memory abilities in APP/PS1 mice. Its mechanism might be related to activation of the cAMP/PKA/CREB-BDNF signaling pathway.
Animals
;
Brain-Derived Neurotrophic Factor/metabolism*
;
Male
;
Cyclic AMP Response Element-Binding Protein/metabolism*
;
Brain/drug effects*
;
Metabolomics
;
Mice, Inbred C57BL
;
Neuronal Plasticity/drug effects*
;
Drugs, Chinese Herbal/therapeutic use*
;
Cyclic AMP-Dependent Protein Kinases/metabolism*
;
Cyclic AMP/metabolism*
;
Reactive Oxygen Species/metabolism*
;
Amyloid beta-Protein Precursor/metabolism*
;
Mice, Transgenic
;
Mice
;
Amyloid beta-Peptides/metabolism*
;
Signal Transduction/drug effects*
;
Alzheimer Disease/drug therapy*
;
Superoxide Dismutase/metabolism*
7.Identification of prognosis-related key genes in hepatocellular carcinoma based on bioinformatics analysis.
Qian XIE ; Yingshan ZHU ; Ge HUANG ; Yue ZHAO
Journal of Central South University(Medical Sciences) 2025;50(2):167-180
OBJECTIVES:
Hepatocellular carcinoma is one of the most common primary malignant tumors with the third highest mortality rate worldwide. This study aims to identify key genes associated with hepatocellular carcinoma prognosis using the Gene Expression Omnibus (GEO) database and provide a theoretical basis for discovering novel prognostic biomarkers for hepatocellular carcinoma.
METHODS:
Hepatocellular carcinoma-related datasets were retrieved from the GEO database. Differentially expressed genes (DEGs) were identified using the GEO2R tool. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID). A protein-protein interaction (PPI) network was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and key genes were identified using Cytoscape software. The University of Alabama at Birmingham Cancer Data Analysis Resource (UALCAN) was used to analyze the expression levels of key genes in normal and hepatocellular carcinoma tissues, as well as their associations with pathological grade, clinical stage, and patient survival. The Human Protein Atlas (THPA) was used to further validate the impact of key genes on overall survival. Expression levels of key genes in the blood of hepatocellular carcinoma patients were evaluated using the expression atlas of blood-based biomarkers in the early diagnosis of cancers (BBCancer).
RESULTS:
A total of 78 DEGs were identified from the GEO database. GO and KEGG analyses indicated that these genes may contribute to hepatocellular carcinoma progression by promoting cell division and regulating protein kinase activity. Sixteen key genes were screened via Cytoscape and validated using UALCAN and THPA. These genes were overexpressed in hepatocellular carcinoma tissues and were associated with disease progression and poor prognosis. Finally, BBCancer analysis showed that ASPM and NCAPG were also elevated in the blood of hepatocellular carcinoma patients.
CONCLUSIONS
This study identified 16 key genes as potential prognostic biomarkers for hepatocellular carcinoma, among which ASPM and NCAPG may serve as promising blood-based markers for hepatocellular carcinoma.
Humans
;
Carcinoma, Hepatocellular/mortality*
;
Liver Neoplasms/pathology*
;
Prognosis
;
Computational Biology/methods*
;
Protein Interaction Maps/genetics*
;
Biomarkers, Tumor/genetics*
;
Gene Expression Regulation, Neoplastic
;
Gene Expression Profiling
;
Gene Ontology
;
Databases, Genetic
8.Identification of shared key genes and pathways in osteoarthritis and sarcopenia patients based on bioinformatics analysis.
Yuyan SUN ; Ziyu LUO ; Huixian LING ; Sha WU ; Hongwei SHEN ; Yuanyuan FU ; Thainamanh NGO ; Wen WANG ; Ying KONG
Journal of Central South University(Medical Sciences) 2025;50(3):430-446
OBJECTIVES:
Osteoarthritis (OA) and sarcopenia are significant health concerns in the elderly, substantially impacting their daily activities and quality of life. However, the relationship between them remains poorly understood. This study aims to uncover common biomarkers and pathways associated with both OA and sarcopenia.
METHODS:
Gene expression profiles related to OA and sarcopenia were retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) between disease and control groups were identified using R software. Common DEGs were extracted via Venn diagram analysis. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted to identify biological processes and pathways associated with shared DEGs. Protein-protein interaction (PPI) networks were constructed, and candidate hub genes were ranked using the maximal clique centrality (MCC) algorithm. Further validation of hub gene expression was performed using 2 independent datasets. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value of key genes for OA and sarcopenia. Mouse models of OA and sarcopenia were established. Hematoxylin-eosin and Safranin O/Fast Green staining were used to validate the OA model. The sarcopenia model was validated via rotarod testing and quadriceps muscle mass measurement. Real-time reverse transcription PCR (real-time RT-PCR) was employed to assess the mRNA expression levels of candidate key genes in both models. Gene set enrichment analysis (GSEA) was conducted to identify pathways associated with the selected shared key genes in both diseases.
RESULTS:
A total of 89 common DEGs were identified in the gene expression profiles of OA and sarcopenia, including 76 upregulated and 13 downregulated genes. These 89 DEGs were significantly enriched in protein digestion and absorption, the PI3K-Akt signaling pathway, and extracellular matrix-receptor interaction. PPI network analysis and MCC algorithm analysis of the 89 common DEGs identified the top 17 candidate hub genes. Based on the differential expression analysis of these 17 candidate hub genes in the validation datasets, AEBP1 and COL8A2 were ultimately selected as the common key genes for both diseases, both of which showed a significant upregulation trend in the disease groups (all P<0.05). The value of area under the curve (AUC) for AEBP1 and COL8A2 in the OA and sarcopenia datasets were all greater than 0.7, indicating that both genes have potential value in predicting OA and sarcopenia. Real-time RT-PCR results showed that the mRNA expression levels of AEBP1 and COL8A2 were significantly upregulated in the disease groups (all P<0.05), consistent with the results observed in the bioinformatics analysis. GSEA revealed that AEBP1 and COL8A2 were closely related to extracellular matrix-receptor interaction, ribosome, and oxidative phosphorylation in OA and sarcopenia.
CONCLUSIONS
AEBP1 and COL8A2 have the potential to serve as common biomarkers for OA and sarcopenia. The extracellular matrix-receptor interaction pathway may represent a potential target for the prevention and treatment of both OA and sarcopenia.
Sarcopenia/genetics*
;
Osteoarthritis/genetics*
;
Computational Biology/methods*
;
Humans
;
Protein Interaction Maps/genetics*
;
Animals
;
Mice
;
Gene Expression Profiling
;
Gene Ontology
;
Transcriptome
;
Male
;
Signal Transduction/genetics*
;
Gene Regulatory Networks
9.Expression of transcription factors in polycystic ovary syndrome.
Qi ZHANG ; Shujuan ZHU ; Bin JIANG
Journal of Central South University(Medical Sciences) 2025;50(3):447-456
OBJECTIVES:
Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women's health. This study aims to investigate gene and transcription factor (TF) expression differences between PCOS patients and healthy individuals using bioinformatics approaches, and to verify the function of key transcription factors, with the goal of providing new insights into the pathogenesis of PCOS.
METHODS:
Differentially expressed genes (DEGs) and differentially expressed transcription factors (DETFs) between PCOS patients and controls were identified from the RNA sequencing dataset GSE168404 using bioinformatics methods. Functional enrichment analysis was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The expression and function of core transcription factors were further validated in ovarian tissues of PCOS model mice and control mice using Western blotting and reverse transcription quantitative polymerase chain reaction (RT-qPCR).
RESULTS:
A total of 332 DEGs were identified between PCOS patients and controls, including 259 upregulated and 73 downregulated genes in the PCOS group. 19 DETFs were further screened, of which 16 were upregulated and 3 were downregulated in PCOS. The upregulated DETFs (including TFCP2L1, DACH1, ESR2, AFF3, SMAD9, ZNF331, HOPX,ATOH8, HIF3α, DPF3, HOXC4, HES1, ID1, JDP2, SOX4, and ID3) were primarily associated with lipid metabolism, development, and cell adhesion. Protein and mRNA expression analysis in PCOS model mice revealed significantly decreased levels of hypoxia-inducible factor (HIF) 1α and HIF2α, and significantly increased expression of HIF3α compared to control mice (all P<0.001).
CONCLUSIONS
Significant differences in gene and TF expression exist between PCOS patients and healthy individuals. HIF-3α may play a crucial role in PCOS and could serve as a novel biomarker for diagnosis and a potential therapeutic target.
Polycystic Ovary Syndrome/metabolism*
;
Female
;
Humans
;
Animals
;
Mice
;
Transcription Factors/metabolism*
;
Computational Biology
;
Gene Expression Profiling
;
Adult
10.Construction of a treatment response prediction model for multiple myeloma based on multi-omics and machine learning.
Xionghui ZHOU ; Rong GUI ; Jing LIU ; Meng GAO
Journal of Central South University(Medical Sciences) 2025;50(4):531-544
OBJECTIVES:
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells and remains incurable. Patients with primary refractory multiple myeloma (PRMM) show poor response to initial induction therapy. This study aims to develop a machine learning-based model to predict treatment response in newly diagnosed multiple myeloma (NDMM) patients, in order to optimize therapeutic strategies.
METHODS:
NDMM and post-treatment MM patients hospitalized in the Department of Hematology, Third Xiangya Hospital, Central South University, between August 2022 and July 2023 were enrolled. Post-treatment MM patients were categorized into PRMM patients and treatment-responsive MM (TRMM) patients based on therapeutic efficacy. Serum metabolites were detected and analyzed via metabolomics. Based on the metabolomics analysis results and combined with transcriptomic sequencing data of NDMM patients from databases, differentially expressed amino acid metabolism-related genes (AAMGs) among post-treatment NDMM patients with varying therapeutic outcomes were screened. Using bioinformatics analyses and machine learning algorithms, a predictive model for treatment response in NDMM was constructed and used to identify patients at risk for PRMM.
RESULTS:
A total of 61 patients were included: 22 NDMM, 23 TRMM, and 16 PRMM patients. Significant differences in metabolite levels were observed among the 3 groups, with differential metabolites mainly enriched in amino acid metabolism pathways. Follow-up data were available for 16 of the 22 NDMM patients, including 12 treatment responders (ND_TR group) and 4 with PRMM (ND_PR group). A total of 23 differential metabolites were identified between these 2 groups: 6 metabolites (e.g., tryptophan) were upregulated and 17 (e.g., citric acid) were downregulated in the ND_TR group. Transcriptomic data from 108 TRMM and 77 PRMM patients were analyzed to identify differentially expressed AAMGs, which were then used to construct a prediction model. The area under the receiver operating characteristic curve (AUC) for the model exceeded 0.8, and AUC values in 3 external validation cohorts were all above 0.7.
CONCLUSIONS
This study delineated the metabolic alterations in MM patients with different treatment response, suggesting that dysregulated amino acid metabolism may be associated with poor treatment response in PRMM. By integrating metabolomics and transcriptomics, a machine learning-based predictive model was successfully established to forecast treatment response in NDMM patients.
Humans
;
Multiple Myeloma/drug therapy*
;
Machine Learning
;
Male
;
Female
;
Metabolomics/methods*
;
Middle Aged
;
Aged
;
Treatment Outcome
;
Transcriptome
;
Computational Biology
;
Adult
;
Multiomics

Result Analysis
Print
Save
E-mail